We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 2,492

The Life Science Industry in Israel
  • Barnea & Co
  • Israel, USA
  • June 12 2017

The life sciences are advancing at dramatic rates in capabilities and goals. For most of human existence, we have been trying to keep up with the


PayerProvider Digital Health Investments Increase in Q1 2017
  • Fenwick & West LLP
  • USA
  • June 1 2017

Last September, we noted that payers and providers were expected to become increasingly active digital health strategic investors given their


The Opportunities and Challenges of Freestanding Emergency Departments
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • May 24 2017

Following our blog post regarding the retail clinic movement, “Patient Check-Ups Before Checking Out: Partnering to Bring Health Care into the


Video- Health care M&A
  • Ropes & Gray LLP
  • USA
  • May 23 2017

John Chesley, a health care partner, discusses M&A deal-making in the industry and the impact of value-based payment models. He also outlines a new


Complicated Landscape Awaits New FDA Commissioner
  • Holland & Knight LLP
  • USA
  • May 9 2017

Dr. Scott Gottlieb's confirmation as Commissioner of Food and Drugs marks an opportunity for Congress and the public to determine whether


Hot Topics: What’s Next for Investing in Health Care
  • Nixon Peabody LLP
  • USA
  • May 3 2017

On May 3, 2017, Nixon Peabody LLP hosted a Hot Topics in the Middle Market event entitled Private Equity Investing Outlook: What is Next for


2017 IPO Study
  • Proskauer Rose LLP
  • European Union, United Kingdom, USA
  • April 12 2017

Welcome to this fourth edition of Proskauer’s IPO Study. In it you will find our analysis


When Approval for a Drug “Indication” Gets Murky: Drafting Milestones to Avoid Disputes
  • Cooley LLP
  • USA
  • April 7 2017

According to a recent study by SRS of recent private life sciences deals, disputes over earn-outs arose in about one-third (36) of all milestones


Merger and Acquisition Activity in the Rehabilitation, Home Health and Hospice Sectors Increased in 2016, But Will this Trend Continue?
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • March 31 2017

Since 2014, there has been a steady increase in mergers and acquisitions in the Rehabilitation sector, with a total of 40 deals announced in 2016


2016 biometer shows strength in early and late stage deals but cracks beneath the surface
  • Morrison & Foerster LLP
  • USA
  • March 30 2017

The 2016 BioMeter showed strength at both ends of the drug-development spectrum, with extremely strong results for pre-clinicaldiscovery transactions